Anastrozole and ZD 1839 in Treating Postmenopausal Women With Metastatic Breast Cancer

Completed · Phase 2

Conditions studied: Breast Cancer

In brief

RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Anastrozole may fight breast cancer by blocking the production of estrogen by the tumor cells. Biological therapies such as ZD 1839 may interfere with the growth of the tumor cells and slow the growth of advanced solid tumors. Combining anastrozole with ZD 1839 may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining anastrozole with ZD 1839 in treating postmenopausal women who have metastatic breast cancer that has not responded to hormone therapy.

Key facts

Study ID

NCT00049062

Run by

The University of Texas Health Science Center at San Antonio

Starts

2002-09-01

Expected to finish

2007-10-01

Last updated by the study team

2013-02-21

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

Where it is running

• Cancer Therapy and Research Center — San Antonio, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.